Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the ASX 200 shares leading Tuesday's market rebound
Healthcare Shares
Top broker says Mesoblast shares can rocket 100%
Healthcare Shares
Broker laments 'catastrophic negative surprise' that highlights the risks with these types of ASX shares
Share Market News
ASX 200 plunges as US tariffs fall-out continues
Share Fallers
Why Domain, Mesoblast, Pro Medicus, and Tuas shares are tumbling today
Healthcare Shares
2 ASX 200 biotech stocks announcing big news today
Healthcare Shares
Bell Potter names the best ASX healthcare stocks to buy now
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Fallers
Why Appen, Mesoblast, Rio Tinto, and Woodside shares are falling today
Healthcare Shares
Why Mesoblast shares could still be dirt cheap even after 700% gain
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
